Nuvilex Announces Preliminary Data from Preclinical Study on Effects of Pancreatic Cancer Treatment on Ascites Fluid Formation
November 19 2014 - 9:30AM
InvestorsHub NewsWire
SILVER SPRING, MD - November 19, 2014 -
InvestorsHub NewsWire - Nuvilex, Inc. (OTCQB:
NVLX), a clinical-stage biotechnology company providing cell
therapy solutions for the treatment of diseases, announced today
that promising preliminary data has been released from the
preclinical animal study on the effects of Nuvilex’s pancreatic
cancer treatment on the accumulation of ascites fluid in
tumor-bearing animals. This study, performed by Nuvilex contractor,
Translational Drug Development (TD2), employed immunosuppressed
mice implanted with disseminated human ovarian cancer cells into
the peritoneal cavity.
Preliminary data analysis suggests that treatment with Nuvilex’s
live-cell encapsulation technology, Cell-in-a-Box® plus
ifosfamide, produces a significant survival advantage as compared
to non-treated control animals. Nuvilex’s treatment appears to be
at least as good as cisplatin, the current standard of care for
ovarian cancer. However, when the encapsulated cells plus
ifosfamide were used in conjunction with cisplatin, the survival
rate was greatly enhanced. The final data analysis will be released
in the future.
“The data itself is not only exciting from an ascites point of
view, but also provides further evidence that encapsulated cells
plus ifosfamide are effective at treating yet another type of
malignant tumor. This provides the rationale for additional
clinical trials of this novel therapy,” said Prof. Dr. Walter H.
Günzburg, the Chief Scientific Officer of Nuvilex.
Nuvilex CEO and President, Kenneth L. Waggoner, stated, “We
couldn’t be more elated with the information we’re receiving from
TD-2 as Nuvilex’s preclinical studies progress. Based on the
preliminary data we’ve received, Nuvilex’s treatment appears to be
performing admirably alone and remarkably as a combination
treatment. This data justifies our decision last year to purchase
the exclusive global rights to further develop
Cell-in-a-Box® cancer treatments.”
About Nuvilex
Nuvilex (OTCQB:
NVLX) is a clinical stage biotechnology company focused on
developing and preparing to commercialize treatments for cancer and
diabetes based upon a proprietary cellulose-based live cell
encapsulation technology known as Cell-in-a-Box®. This
unique and patented technology will be used as a platform upon
which treatments for several types of cancer, including advanced,
inoperable pancreatic cancer, and diabetes are being built.
Nuvilex's treatment for pancreatic cancer involves the well-known
anticancer prodrug ifosfamide, together with encapsulated live
cells, which convert ifosfamide into its active or "cancer-killing"
form. Nuvilex is also working towards improving the quality of life
for patients with advanced pancreatic cancer and on treatments for
other types of solid cancerous tumors. In addition, Nuvilex is
developing treatments for cancer based upon chemical constituents
of marijuana known as cannabinoids. Nuvilex is examining ways to
exploit the benefits of Cell-in-a-Box® technology in
optimizing the anticancer effectiveness of cannabinoids, while
minimizing or outright eliminating the debilitating side effects
usually associated with cancer treatments. This provides Nuvilex a
unique opportunity to develop “green” approaches to fighting deadly
cancers, such as those of the pancreas, brain and breast, which
affect hundreds of thousands of individuals worldwide every
year.
Safe Harbor
This press release may contain forward-looking
statements regarding Nuvilex and its future events and results that
involve inherent risks and uncertainties. The words "anticipate,"
"believe," "estimate," "expect," "intend," "plan" and similar
expressions, as they relate to Nuvilex or its management, are
intended to identify forward-looking statements. Important factors,
many of which are beyond the control of Nuvilex, that could cause
actual results to differ materially from those set forth in the
forward-looking statements include Nuvilex's ability to continue as
a going concern, delays or unsuccessful results in clinical trials
or flaws or defects regarding its product candidates, changes in
relevant legislation or regulatory requirements, uncertainty of
protection of Nuvilex's intellectual property and Nuvilex's
continued ability to raise capital. Nuvilex does not assume any
obligation to update any of these forward-looking statements.
More information about Nuvilex can be found at www.nuvilex.com. It can also be obtained by contacting
Investor Relations.
Investor Relations Contacts:
Clare Matschullat
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 106
cmatschullat@bplifescience.com